Morgan Stanley
INO icon

Morgan Stanley’s Inovio Pharmaceuticals INO Stock Holding History

Morgan Stanley’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.3K Sell
50,256
-13,608
-21% -$16.1K ﹤0.01% 6473
2026
Q1 		$111K Sell
63,864
-41,964
-40% -$69.1K ﹤0.01% 6112
2025
Q4 		$184K Sell
105,828
-680,946
-87% -$1.5M ﹤0.01% 5961
2025
Q3 		$1.84M Buy
786,774
+384,912
+96% +$737K ﹤0.01% 4837
2025
Q2 		$818K Buy
401,862
+117,219
+41% +$225K ﹤0.01% 5211
2025
Q1 		$464K Buy
284,643
+151,366
+114% +$304K ﹤0.01% 5361
2024
Q4 		$244K Buy
133,277
+38,145
+40% +$169K ﹤0.01% 5715
2024
Q3 		$550K Sell
95,132
-8,574
-8% -$70.7K ﹤0.01% 5357
2024
Q2 		$838K Buy
103,706
+34,832
+51% +$367K ﹤0.01% 5068
2024
Q1 		$956K Sell
68,874
-21,409
-24% -$185K ﹤0.01% 4969
2023
Q4 		$553K Buy
90,283
+64,930
+256% +$320K ﹤0.01% 5578
2023
Q3 		$118K Sell
25,353
-6,037
-19% -$33.3K ﹤0.01% 5801
2023
Q2 		$168K Sell
31,390
-11,841
-27% -$95.5K ﹤0.01% 5716
2023
Q1 		$425K Sell
43,231
-61,559
-59% -$1.05M ﹤0.01% 5347
2022
Q4 		$1.96M Sell
104,790
-2,948
-3% -$66.8K ﹤0.01% 4479
2022
Q3 		$2.23M Sell
107,738
-119,519
-53% -$3.06M ﹤0.01% 4354
2022
Q2 		$4.72M Buy
227,257
+89,398
+65% +$2.52M ﹤0.01% 3822
2022
Q1 		$5.94M Buy
137,859
+94,069
+215% +$4.24M ﹤0.01% 3492
2021
Q4 		$2.62M Sell
43,790
-17,659
-29% -$1.41M ﹤0.01% 4355
2021
Q3 		$5.28M Sell
61,449
-7,723
-11% -$775K ﹤0.01% 3626
2021
Q2 		$7.69M Buy
69,172
+44,956
+186% +$4.32M ﹤0.01% 3295
2021
Q1 		$2.7M Sell
24,216
-23,874
-50% -$3.14M ﹤0.01% 4021
2020
Q4 		$5.11M Sell
48,090
-5,492
-10% -$731K ﹤0.01% 3234
2020
Q3 		$7.46M Buy
53,582
+30,686
+134% +$6.4M ﹤0.01% 2313
2020
Q2 		$7.41M Buy
22,896
+3,833
+20% +$615K ﹤0.01% 2262
2020
Q1 		$1.7M Sell
19,063
-96,904
-84% -$5.97M ﹤0.01% 3498
2019
Q4 		$4.59M Buy
115,967
+104,268
+891% +$3.14M ﹤0.01% 3289
2019
Q3 		$287K Buy
11,699
+4,032
+53% +$123K ﹤0.01% 4949
2019
Q2 		$271K Sell
7,667
-2,997
-28% -$119K ﹤0.01% 4884
2019
Q1 		$477K Sell
10,664
-9,336
-47% -$471K ﹤0.01% 4568
2018
Q4 		$960K Sell
20,000
-5,944
-23% -$361K ﹤0.01% 4307
2018
Q3 		$1.73M Sell
25,944
-2,044
-7% -$114K ﹤0.01% 4125
2018
Q2 		$1.32M Buy
27,988
+1,526
+6% +$84.2K ﹤0.01% 4427
2018
Q1 		$1.5M Buy
26,462
+907
+4% +$49.1K ﹤0.01% 4250
2017
Q4 		$1.27M Sell
25,555
-48,323
-65% -$3M ﹤0.01% 4385
2017
Q3 		$5.62M Buy
73,878
+5,510
+8% +$410K ﹤0.01% 2844
2017
Q2 		$6.43M Buy
68,368
+13,359
+24% +$1.14M ﹤0.01% 2594
2017
Q1 		$4.37M Sell
55,009
-15,210
-22% -$1.21M ﹤0.01% 2988
2016
Q4 		$5.85M Buy
70,219
+19,813
+39% +$1.79M ﹤0.01% 2833
2016
Q3 		$5.64M Buy
50,406
+3,672
+8% +$406K ﹤0.01% 2548
2016
Q2 		$5.18M Sell
46,734
-2,857
-6% -$347K ﹤0.01% 2587
2016
Q1 		$5.18M Sell
49,591
-19,240
-28% -$1.49M ﹤0.01% 2495
2015
Q4 		$5.55M Buy
68,831
+6,543
+11% +$521K ﹤0.01% 2566
2015
Q3 		$4.32M Buy
62,288
+10,864
+21% +$947K ﹤0.01% 2788
2015
Q2 		$5.04M Sell
51,424
-2,159
-4% -$231K ﹤0.01% 2788
2015
Q1 		$5.25M Sell
53,583
-659
-1% -$63.8K ﹤0.01% 2711
2014
Q4 		$5.98M Sell
54,242
-24,306
-31% -$2.97M ﹤0.01% 2555
2014
Q3 		$9.28M Buy
78,548
+4,082
+5% +$509K ﹤0.01% 2097
2014
Q2 		$9.66M Buy
74,466
+36,261
+95% +$4.28M ﹤0.01% 2067
2014
Q1 		$6.11M Buy
38,205
+19,955
+109% +$2.86M ﹤0.01% 2379
2013
Q4 		$2.54M Sell
18,250
-1,776
-9% -$178K ﹤0.01% 3200
2013
Q3 		$1.99M Buy
20,026
+9,393
+88% +$787K ﹤0.01% 3218
2013
Q2 		$406K Buy
+10,633
New +$322K ﹤0.01% 4404

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley's INO Position: Q2 2026 in Review

Morgan Stanley reduced its Inovio Pharmaceuticals (INO) stake by 21% in Q2 2026, selling an estimated $16.1K and leaving 50,256 shares worth $55.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6473.

Morgan Stanley first reported a position in INO in Q2 2013 and has held it in 53 quarters since. The position peaked at $9.66M in Q2 2014. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Morgan Stanley held 50,256 shares of Inovio Pharmaceuticals worth $55.3K as of Q2 2026.
  • Morgan Stanley sold 13,608 Inovio Pharmaceuticals shares in Q2 2026, an estimated $16.1K.
  • Inovio Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6473 holding.
  • Morgan Stanley first reported a position in Inovio Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Morgan Stanley's Inovio Pharmaceuticals position peaked at $9.66M in Q2 2014.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.